Anika Therapeutics
ANIK· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock -41.6% in FY2025
Stephen D. Griffin is the CEO of Anika Therapeutics and was paid $2.0M in FY2025 (Dec), down 23%.
Pay$100 in the stock at the end of FY23 → $42
Executives5
See all- 1Cheryl R. Blanchard, Ph.D.Executive Chair; Former President and Chief Executive OfficerFY2025
- 2Stephen D. GriffinPresident and Chief Executive Officer; Former EVP, Chief Financial Officer and Chief Operating OfficerFY2025
- 3David B. Colleran EVPGeneral Counsel and SecretaryFY2025
- 4Anne M. NunesFormer SVP, Chief Operations OfficerFY2024
- 5Ian W. McLeodSVP, Chief Accounting Officer and TreasurerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allAnika Therapeutics paid its 4 named executives $9.3M in total in FY2025 (Dec). CEO Stephen D. Griffin was paid $2.0M of that.
| Name | |||
|---|---|---|---|
| Cheryl R. Blanchard, Ph.D.Executive Chair; Former President and Chief Executive Officer | |||
| Stephen D. GriffinPresident and Chief Executive Officer; Former EVP, Chief Financial Officer and Chief Operating Officer | Not disclosed | ||
| David B. Colleran EVPGeneral Counsel and Secretary | |||
| Ian W. McLeodSVP, Chief Accounting Officer and Treasurer | Not disclosed | Not disclosed | |
| Anne M. NunesFormer SVP, Chief Operations Officer | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers17
See all
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board1
See all- Stephen D. GriffinDirector · -1 yr on the boardNot independent—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 28, 2026 | FY2025 |
| Annual report | 10-K | Mar 3, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 28, 2025 | FY2024 |
| Annual report | 10-K | Mar 17, 2025 | FY2024 |
| Proxy statement | DEF 14A | Jun 11, 2024 | FY2023 |
| Annual report | 10-K | Mar 15, 2024 | FY2023 |
